Sanofi-Aventis

Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health...

Smallpox vaccine Aventis

Haemophilus b Vaccine Aventis

DTP Vaccine Aventis

Lyme Vaccine rDNA Aventis

sanofi-aventis’ New Direction

Since Chris Viehbacher joined sanofi-aventis as CEO his aim has been to get the company recognised as a global healthcare company and not solely as a producer of vaccines. Jean-Claude Muller, Senior V...

Sanofi US Agrees to Pay $109 Million to Resolve False Claims Act Allegations of Free Product Kickbacks to Physicians

Sanofi-Aventis U.S. Inc. and Sanofi-Aventis U.S. LLC, subsidiaries of international drug manufacturer Sanofi (collectively, Sanofi US), have agreed to pay $109 million to resolve allegations that Sano...

Sanofi-Aventis übertrifft Gewinnprognosen

Paris (BoerseGo.de) - Der französische Pharmakonzern Sanofi-Aventis hat am heutigen Donnerstag seine Zahlen zum vierten Quartal ausgewiesen. Demnach musste das im EuroStoxx 50 gelistete Unternehmen.....

Sanofi-Aventis pharma partners with Covis for several drugs

Covis Pharma pharma partners with sanofi-aventis to acquire full commercial rights for Nilandron (nilutamide), Plaquenil (hydroxychloroquine), Rilutek (riluzole), Uroxatral (alfuzosin hydrochloride)...

Epistem announces collaboration with Sanofi Aventis

Epistem plc, the UK biotechnology and personalised medicine company today announced a collaboration with sanofi-aventis U.S. Inc. relating to the use of Epistem's proprietary biomarker gene expression...

Sanofi-aventis withdraws its marketing authorisation application for Mulsevo

The EMA has been notified by Sanofi-aventis of its decision to withdraw its marketing authorisation application for Mulsevo...

News and press releases: Sanofi-aventis withdraws its marketing authorisation application for Mulsevo (semuloparin sodium)

The European Medicines Agency has been formally notified by Sanofi-aventis of its decision to withdraw its application for a centralised marketing authorisation for the medicine Mulsevo (semuloparin s...

Nichiiko Sanofi Japan Gets Permission From Sanofi To Sell Anti-Allergy Allegra Generic From June

Nichiiko’s and Sanofi’s joint venture company Nichiiko Sanofi Aventis was given permission to exclusively produce and market SANIK, the generic version of Sanofi’s anti-allergy drug Allegra (fex...

Hepatitis C - pipeline update.

Synthesis of new bridgehead substituted azabicyclo-2.2.1heptane and -3.3.1nonane derivatives as potent and selective α7 nicotinic ligands.

New azabicyclo[2.2.1]heptane and -[3.3.1]nonane derivatives containing a pyridinyl substituent at the bridgehead position have been synthesized via an efficient ten chemical steps pathway. Both chemic...

Fragment deconstruction of small, potent factor xa inhibitors: exploring the superadditivity energetics of fragment linking in protein-ligand complexes.

More than just the sum of its parts: The superadditivity effect of fragment linking on ΔG was quantified by deconstructing two fXa inhibitors with congeneric fragments, but different linkers. By conn...

Inside back cover: fragment deconstruction of small, potent factor xa inhibitors: exploring the superadditivity energetics of fragment linking in protein-ligand complexes (angew. Chem. Int. Ed. 4/2012).

The superadditivity of fragment linking on affinities was quantified by systematic deconstruction of a fXa inhibitor. In their Communication on page 905 ff., M. Nazaré, H. Matter, and co-workers...

Academia-industry alliance: Belfer Institute and sanofi-aventis collaborate to develop new cancer therapeutics.